This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Perrigo Acquisition Of Velcera, Inc. -- Known For Its PetArmor® Franchise Of Flea And Tick Treatments -- Closes Today

YARDLEY, Pa., April 1, 2013 /PRNewswire/ -- The sale of privately-held Velcera, Inc. ("Velcera") — a leading pet health company committed to providing consumers with best-in-class pet health products that contain the same active ingredients as branded veterinary products but at a significantly lower cost — to Allegan-Mich.-based Perrigo Company (Nasdaq: PRGO; TASE) closed today for approximately $160 million in cash.

Velcera and its FidoPharm subsidiary is best known for its flea and tick treatment PetArmor ®, which is the No. 1 generic of Frontline ® Top Spot containing the No. 1 vet-recommended active ingredient for flea and tick protection. PetArmor ® is backed by 20 clinical trials to prove its effectiveness and safety. PetArmor's ® money-back "Protection Guarantee" promises to protect your dog or cat as well as Frontline ® products or PetArmor ® will refund the purchase price.

Velcera, together with major retail partners, has been instrumental in developing an OTC market for pet health products traditionally dispensed primarily by veterinarians. Retail sales of the PetArmor ® franchise exceeded $100 million during calendar year 2012, the value-brand's first full year on the market, having launched in April 2011.

Under Perrigo, the PetArmor ® franchise brand will continue to enjoy the same broad distribution at retailers nationwide that pet consumers have come to expect since PetArmor ® launched two years ago.

"The extraordinary synergies between Velcera and Perrigo means that even more pet owners can receive best-in-class pet health products," said Dennis Steadman, Velcera's president and CEO.

To learn more about PetArmor ®, visit www.PetArmor.comFacebook:

Frontline ® is the registered trademark of Merial Frontline ® and Merial are not affiliated with PetArmor ®


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FB $103.78 2.70%
GOOG $688.21 0.60%
TSLA $151.97 5.80%
YHOO $27.04 -0.22%
AAPL $93.62 -0.69%


Chart of I:DJI
DOW 15,762.57 +102.39 0.65%
S&P 500 1,842.49 +13.41 0.73%
NASDAQ 4,306.4130 +39.5760 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs